Authors
Nicholas Lintzeris, Llewellyn Mills, Adrian Dunlop, Jan Copeland, Iain Mcgregor, Raimondo Bruno, Adrienne Kirby, Mark Montebello, Michelle Hall, Meryem Jefferies, Richard Kevin, Anjali Bhardwaj, Agonist Replacement For Cannabis Dependence Study Group
Publication date
2020/10/1
Journal
Drug and Alcohol Dependence
Volume
215
Pages
108220
Publisher
Elsevier
Description
Introduction and Aims
Previous studies suggest cannabinoid agonist treatment is effective in reducing cannabis use in dependent treatment seekers, however few studies have reported on post-treatment outcomes. We examine cannabis use outcomes 12 weeks after cessation of treatment from a randomised placebo-controlled trial of nabiximols for the treatment of cannabis dependence.
Method
128 participants received either nabiximols (n = 61) or placebo (n = 67) for 12 weeks, in combination with psychosocial interventions. Self-reported number of days of cannabis use in the previous 28 days was measured at baseline, 4, 8, and 12 weeks (end of treatment) and again at 24 weeks (3 months after treatment ceased). Urinalysis was used to confirm self-report data at Week 24 interview.
Results
A factorial mixed-effects model for repeated measures regression revealed that the nabiximols group used cannabis on 6.8 …
Scholar articles
N Lintzeris, L Mills, A Dunlop, J Copeland, I Mcgregor… - Drug and Alcohol Dependence, 2020